Abstract
We compared the outcomes of 2,500 patients who suffered from previous cerebrovascular disorders (transient ischemic attacks, reversible ischemic neurologic deficits, or completed strokes) treated with acetylsalicylic acid plus dipyridamole or matched placebo and followed for 2 years. Treatment was associated with a 33.5% reduction (p less than 0.001) in the incidence of all end points (deaths from all causes or strokes) by intention-to-treat analysis and a 36.5% reduction (p less than 0.001) by explanatory analysis. End point reduction appeared to be similar in men and women. The effect of treatment was similar regardless of the patients' age, nature of the qualifying cerebrovascular event, site of the responsible lesion, and diastolic blood pressure. Our results demonstrate the efficacy of combined therapy, but the efficacy of acetylsalicylic acid or dipyridamole alone and the most effective acetylsalicylic acid dosage remain in question.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Advanced and Specialized Nursing,Cardiology and Cardiovascular Medicine,Neurology (clinical)
Reference25 articles.
1. A Randomized Trial of Aspirin and Sulfinpyrazone in Threatened Stroke
2. Comparative trial of sulfinpyrazone and aspirin+dipyridamole in acute myocardial infarction;Misra NP;Curr TherRes,1983
3. Sulfinpyrazone in the Prevention of Sudden Death after Myocardial Infarction
4. Polli EE Cortellaro M: The Anturan Reinfarction Study in Polli EE Cortellaro M (eds): Secondary Prevention of Ischaemic Cardiac Events: Present Status and New Perspectives. Berne Hans Huber 1983 pp 51-60
5. Anturan Reinfarction Italian Study: Sulphinpyrazone in postmyocardial infarction. Lancet 1982;l:237-242
Cited by
100 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献